IBM’s Watson Health Unit is forming several collaborations to facilitate personalized health on a massive scale.
While support services are important, manufacturers must be aware of both state and Federal regulations, as there can be conflicts and differences in interpretations.
Acquisitions and joint ventures with Asian medical companies can provide many advantages for Western firms looking to grow their businesses in Asian medical device markets.
Prior “aggressive” tactics of manufacturers launching new technology can poison the reimbursement environment for a related, but distinct technology occupying the same space. This discussion traces the history of two of the most challenging reimbursement environments: wound healing and spine technologies.
Cardinal CEO George Barrett has said that the company may make more acquisitions in cardiology and endovascular treatment as well as in the trauma and wound care segment.
There are great opportunities for foreign medical device companies in China as the people want better healthcare, the government is increasing access to healthcare, and the market is growing between 15 and 20 percent per year. But access to the marketplace is harder than ever. Why?
Bloomberg reports that the world’s largest healthcare company Johnson & Johnson is in talks with Cardinal Health Inc. to sell its Cordis unit. The unit may fetch as much as $2 billion in a sale, according to the story.
The company’s heart devices such as implantable defibrillators, artificial valves and devices to treat atrial fibrillation, contributed to a 5 percent increase in sales in the cardiac and vascular business, its largest unit.
According to recent analysis by PwC, deal volume declined from 13 deals in the third quarter of 2014 to 9 deals in the fourth quarter. However, deal value increased from $3.7 billion to $4.9 billion over the same period.
The new PMD Act was based on previous ordinances implemented in the summer of 2014. Two of the main points of this revision are to increase safety measures for medical devices and introduce new cellular and tissue therapeutic product regulations.